# Research Proposal: OpenTrialAI - Democratizing Clinical Trial Optimization Through Open-Source Decision Support

## 1. Title

**OpenTrialAI: A Modular Open-Source Framework for Democratizing Clinical Trial Decision Support in Academic Medical Centers**

## 2. Introduction

### 2.1 Background

Clinical trial optimization represents one of the most critical yet underserved applications of artificial intelligence in drug development. While AI has demonstrated transformative potential across early-stage drug discovery—from molecular property prediction to structure-based design—its application to late-stage clinical trials remains concentrated in proprietary commercial platforms. Current commercial solutions such as Lifebit, Medidata, and ConcertAI have achieved impressive performance metrics, including 65% enrollment improvements and 30-50% timeline acceleration. However, these platforms impose annual licensing costs ranging from $100,000 to $500,000, creating insurmountable barriers for academic medical centers that conduct the majority of investigator-initiated trials.

This cost-opacity divide has profound consequences for the drug development ecosystem. Academic researchers, who have historically driven methodological innovation in clinical trial design, are systematically excluded from contributing algorithmic advances to trial optimization. The concentration of clinical trial AI exclusively in commercial hands prevents the transparent, reproducible research that characterizes other domains of computational drug discovery. Despite the availability of over 450,000 publicly accessible trial records in registries such as ClinicalTrials.gov and EudraCT, no open-source alternatives exist to leverage this data for accessible decision support tools.

Recent advances in open-source medical AI frameworks provide compelling precedents for democratization. The MONAI framework for medical imaging, with 774 citations and global adoption across research, clinical, and industrial teams, demonstrates that consortium-maintained open-source tools can achieve widespread impact in healthcare settings. Similarly, molecular design tools like Chemprop (2,200+ GitHub stars) and DiffSBDD (343 citations, 446 GitHub stars) have established thriving ecosystems where community contributions drive continuous innovation. These successes suggest that the Open Science Framework principles—modularity, transparency, and community governance—can transfer to clinical trial workflows.

### 2.2 Research Objectives

This research proposes **OpenTrialAI**, a modular open-source framework designed to democratize access to clinical trial decision support for academic medical centers. The primary objectives are:

**Objective 1: Technical Development** - Design and implement a production-ready, modular framework comprising four independent decision support modules: (1) Patient Recruitment Engine, (2) Protocol Optimizer, (3) Outcome Predictor, and (4) Safety Monitor. Each module will be trained on public trial registries and deployable via standardized APIs compatible with institutional FHIR/HL7 systems.

**Objective 2: Democratization Validation** - Achieve measurable academic adoption through: (a) ≥10 institutional deployments within 12 months of release, (b) ≥5 peer-reviewed publications utilizing the framework within 18 months, and (c) System Usability Scale (SUS) scores ≥70 from clinical trial coordinators, demonstrating practical utility for non-technical users.

**Objective 3: Regulatory Pathway Establishment** - Obtain FDA Class II 510(k) clearance for clinical decision support within 24 months, establishing a precedent for open-source medical AI tools in regulatory contexts and providing a transparent audit trail for algorithmic decision-making.

**Objective 4: Sustainable Ecosystem Creation** - Establish a consortium governance model with 5-10 academic medical centers committed to distributed maintenance, targeting ≥12 community code contributions within 18 months to demonstrate ecosystem viability.

### 2.3 Research Hypothesis

The core hypothesis posits that **Cost-Transparency-Modularity convergence** drives academic adoption of clinical trial AI:

**Main Hypothesis (H1):** A modular, open-source clinical trial decision support framework (OpenTrialAI) trained on public trial registries and equipped with web-based interfaces and consortium maintenance will democratize access to clinical trial AI, enable academic research contributions, and provide regulatory transparency comparable to commercial platforms, thereby achieving ≥10 institutional adoptions within 12 months and ≥5 research publications within 18 months.

This hypothesis rests on a three-stage causal mechanism:

1. **Cost Barrier Removal**: Open-source licensing eliminates $100K-500K annual fees, enabling institutions to redirect budgets from software licenses to deployment infrastructure (GPU servers, IT support).

2. **Transparency-Driven Innovation**: Source code access enables algorithmic inspection, verification, and extension, reducing research friction compared to proprietary black-box systems and increasing publication potential.

3. **Network Effects Through Modularity**: A plug-and-play architecture allows institutions to deploy subsets matching their needs, while consortium governance distributes maintenance burden, creating self-sustaining ecosystem dynamics.

The framework explicitly targets 50-60% of commercial platform performance (30-40% improvement versus 65% baseline) while achieving democratization goals that commercial platforms cannot provide due to proprietary constraints. Success is defined not by matching commercial performance, but by enabling academic research innovation previously blocked by cost and opacity barriers.

### 2.4 Significance

This research addresses a critical gap in the AI for drug development landscape. While molecular design tools have embraced open-source principles, clinical trial optimization remains a proprietary domain. OpenTrialAI's significance spans three dimensions:

**Scientific Impact**: Establishes the first systematic framework for democratizing clinical trial AI access, extending Open Science Framework principles from early-stage drug discovery to late-stage development. This work contributes theoretical understanding of how cost-transparency-modularity convergence enables technology democratization in regulated healthcare contexts.

**Methodological Impact**: Introduces a novel 3-tier architectural pattern (API Layer, Analysis Engine, Web GUI) adapted from molecular design tools to clinical workflows, enabling academic researchers to contribute domain-specific modules (e.g., oncology recruitment, rare disease protocol optimization) without modifying core infrastructure.

**Practical Impact**: Provides immediate cost savings ($100K-500K annually per institution) while enabling algorithmic transparency required for publishing novel trial optimization methods. Long-term, this creates a clinical trial AI ecosystem comparable to molecular design tool ecosystems, where community contributions drive innovation rather than commercial vendor roadmaps.

## 3. Methodology

### 3.1 Overall Research Design

The research employs a mixed-methods approach combining software engineering, machine learning development, and quasi-experimental evaluation across three phases:

**Phase 1 (Months 1-8): Framework Development** - Design and implement core architecture with initial module prototypes.

**Phase 2 (Months 9-16): Multi-Site Pilot Deployment** - Deploy framework at 50 academic medical centers with randomized feature configurations to test causal mechanisms.

**Phase 3 (Months 17-24): Regulatory Submission and Ecosystem Evaluation** - Pursue FDA 510(k) clearance while measuring research productivity and consortium sustainability.

### 3.2 Data Collection and Preparation

#### 3.2.1 Public Trial Registry Data Acquisition

**Data Sources:**
- **ClinicalTrials.gov**: Primary source (~400,000 trials), accessed via AACT (Aggregate Analysis of ClinicalTrials.gov) PostgreSQL database
- **EudraCT**: European Union Clinical Trials Register (~50,000 trials), accessed via XML downloads
- **ANZCTR**: Australian New Zealand Clinical Trials Registry (~20,000 trials), supplementary source

**Data Fields Extracted:**
- Protocol metadata: NCT ID, title, phase, status, dates (start, completion, results posted)
- Eligibility criteria: Inclusion/exclusion criteria text, age ranges, sex, healthy volunteers
- Study design: Allocation, intervention model, masking, primary purpose
- Arms and interventions: Intervention types, descriptions, dosages
- Outcome measures: Primary/secondary endpoints, time frames
- Enrollment: Target sample size, actual enrollment, recruitment status
- Results: Participant flow, baseline characteristics, outcome measures, adverse events (when available)

**Data Preprocessing Pipeline:**
```python
# Pseudocode for data preprocessing
def preprocess_trial_data(raw_trials):
    """
    Standardize and clean trial registry data
    """
    processed = []
    for trial in raw_trials:
        # Text normalization
        trial.criteria = normalize_text(trial.eligibility_criteria)
        trial.interventions = extract_interventions(trial.arms)
        
        # Feature engineering
        trial.complexity_score = calculate_protocol_complexity(
            num_arms=len(trial.arms),
            num_endpoints=len(trial.outcomes),
            criteria_length=len(trial.criteria.split())
        )
        
        # Outcome labeling
        trial.success_label = label_trial_success(
            enrollment_rate=trial.actual / trial.target,
            completion_status=trial.status,
            results_posted=trial.has_results
        )
        
        processed.append(trial)
    
    return processed
```

**Data Quality Assurance:**
- **Completeness filtering**: Retain trials with ≥80% field completion for critical variables (eligibility criteria, interventions, primary outcome)
- **Temporal validation**: Exclude trials with inconsistent dates (completion before start)
- **Deduplication**: Identify and merge duplicate registrations across databases using NCT ID and protocol similarity
- **Stratified sampling**: Ensure training data represents diverse phases (I-IV), therapeutic areas, and sponsor types (academic vs. industry)

**Expected Dataset Statistics:**
- Training set: ~300,000 trials (70%)
- Validation set: ~65,000 trials (15%)
- Test set: ~65,000 trials (15%)
- Temporal split: Training on trials registered before 2020, validation 2020-2021, test 2022-2024

### 3.3 Framework Architecture

#### 3.3.1 Three-Tier Modular Design

**Tier 1: API Layer (Institutional Integration)**

Standardized RESTful interfaces enabling integration with hospital IT systems:

```python
# API endpoint specification
@app.route('/api/v1/recruitment/predict', methods=['POST'])
def predict_recruitment_feasibility(protocol_data):
    """
    Input: JSON with eligibility criteria, target enrollment, timeline
    Output: Feasibility score [0-1], recommended modifications, 
            similar historical trials
    """
    # FHIR-compatible input validation
    validated = validate_fhir_protocol(protocol_data)
    
    # Module invocation
    prediction = recruitment_engine.predict(validated)
    
    # Audit trail logging
    log_prediction(user_id, protocol_id, prediction, timestamp)
    
    return jsonify(prediction)
```

**Tier 2: Analysis Engine (Four Independent Modules)**

**Module 1: Patient Recruitment Engine**

*Objective*: Predict recruitment feasibility and recommend eligibility criteria modifications.

*Architecture*: Transformer-based text encoder (BioBERT fine-tuned on trial criteria) + gradient boosting for tabular features.

*Training Objective*:
$$\mathcal{L}_{\text{recruit}} = \mathcal{L}_{\text{feasibility}} + \lambda \mathcal{L}_{\text{timeline}}$$

where:
$$\mathcal{L}_{\text{feasibility}} = -\sum_{i=1}^{N} y_i \log(\hat{y}_i) + (1-y_i)\log(1-\hat{y}_i)$$

Binary cross-entropy for recruitment success (achieving ≥80% target enrollment), and:

$$\mathcal{L}_{\text{timeline}} = \frac{1}{N}\sum_{i=1}^{N} |\text{days}_i^{\text{actual}} - \text{days}_i^{\text{predicted}}|$$

Mean absolute error for recruitment duration prediction.

*Input Features*:
- Eligibility criteria embeddings (768-dim BioBERT)
- Protocol complexity score (number of arms, endpoints, procedures)
- Therapeutic area (oncology, cardiology, etc.)
- Geographic location and site characteristics
- Historical enrollment rates for similar trials

*Output*:
- Recruitment feasibility score $\in [0,1]$
- Predicted enrollment timeline (days to target)
- Recommended criteria relaxations ranked by impact

**Module 2: Protocol Optimizer**

*Objective*: Assess protocol feasibility and suggest design improvements.

*Architecture*: Multi-task learning framework with shared protocol encoder and task-specific heads.

*Model Formulation*:
$$\mathbf{h}_{\text{protocol}} = \text{Encoder}(\text{criteria}, \text{interventions}, \text{endpoints})$$

$$\hat{y}_{\text{complexity}} = \text{Head}_{\text{complexity}}(\mathbf{h}_{\text{protocol}})$$

$$\hat{y}_{\text{dropout}} = \text{Head}_{\text{dropout}}(\mathbf{h}_{\text{protocol}})$$

$$\hat{y}_{\text{cost}} = \text{Head}_{\text{cost}}(\mathbf{h}_{\text{protocol}})$$

*Training Objective*:
$$\mathcal{L}_{\text{protocol}} = \alpha \mathcal{L}_{\text{complexity}} + \beta \mathcal{L}_{\text{dropout}} + \gamma \mathcal{L}_{\text{cost}}$$

with task-specific losses weighted by uncertainty (learned via homoscedastic task uncertainty).

*Recommendation Engine*:
Uses counterfactual reasoning to suggest protocol modifications:

$$\text{Impact}(\text{modification}) = \mathbb{E}[\hat{y}_{\text{success}}|\text{do}(\text{protocol}^{\text{modified}})] - \mathbb{E}[\hat{y}_{\text{success}}|\text{protocol}^{\text{original}}]$$

**Module 3: Outcome Predictor**

*Objective*: Forecast trial success probability and primary endpoint achievement.

*Architecture*: Ensemble of gradient boosting (XGBoost) and neural network (TabNet) for heterogeneous tabular data.

*Prediction Targets*:
- Trial completion probability: $P(\text{status} = \text{completed})$
- Primary endpoint achievement: $P(\text{endpoint met})$
- Publication likelihood: $P(\text{results published})$

*Calibration*:
Applies Platt scaling for probability calibration:

$$P_{\text{calibrated}}(y=1|x) = \sigma(a \cdot \text{logit}(P_{\text{raw}}(y=1|x)) + b)$$

where $a, b$ are learned on validation set to minimize Brier score:

$$\text{BS} = \frac{1}{N}\sum_{i=1}^{N}(P_i - y_i)^2$$

**Module 4: Safety Monitor**

*Objective*: Identify potential safety signals and adverse event risks.

*Architecture*: Anomaly detection using isolation forests + rule-based alerts for known risk patterns.

*Risk Scoring*:
$$\text{Risk}_{\text{AE}} = w_1 \cdot \text{Score}_{\text{intervention}} + w_2 \cdot \text{Score}_{\text{population}} + w_3 \cdot \text{Score}_{\text{historical}}$$

where:
- $\text{Score}_{\text{intervention}}$: Known adverse event profile from drug databases (DrugBank, FAERS)
- $\text{Score}_{\text{population}}$: Vulnerability based on age, comorbidities, concomitant medications
- $\text{Score}_{\text{historical}}$: Adverse event rates in similar historical trials

*Alert Thresholds*:
- **High risk** (red): Risk score > 0.75 or known black-box warnings
- **Moderate risk** (yellow): Risk score 0.50-0.75
- **Low risk** (green): Risk score < 0.50

**Tier 3: Web GUI Layer (Clinical User Interface)**

*Design Principles*:
- **Simplicity**: Single-page application with wizard-style workflows
- **Transparency**: All recommendations include explanations and supporting evidence (similar historical trials)
- **Clinical language**: Avoid ML jargon, use clinical terminology

*Key Interface Components*:
1. **Protocol Upload**: Drag-and-drop for protocol PDFs with automatic text extraction
2. **Dashboard**: Visual summary of feasibility scores across all modules
3. **Recommendation Cards**: Actionable suggestions with impact estimates and confidence intervals
4. **Historical Comparisons**: Interactive table of similar trials with filtering by therapeutic area, phase, sponsor
5. **Export**: Generate PDF reports for IRB submissions or protocol amendments

*Usability Target*: System Usability Scale (SUS) ≥70, measured via standardized questionnaire administered to ≥30 clinical trial coordinators per deployment site.

#### 3.3.2 Training Procedures

**Transfer Learning Strategy:**

1. **Pre-training**: Initialize text encoders with BioBERT (pre-trained on PubMed abstracts + clinical notes)
2. **Domain Adaptation**: Continue pre-training on trial protocol corpus using masked language modeling:
$$\mathcal{L}_{\text{MLM}} = -\sum_{i \in \text{masked}} \log P(w_i | \mathbf{w}_{\setminus i})$$

3. **Fine-tuning**: Task-specific fine-tuning on labeled trial outcomes with early stopping based on validation performance

**Hyperparameter Optimization:**

Bayesian optimization (using Optuna library) over:
- Learning rate: $\{10^{-5}, 10^{-4}, 10^{-3}\}$
- Batch size: $\{16, 32, 64\}$
- Dropout rate: $\{0.1, 0.2, 0.3\}$
- Loss weights: $\alpha, \beta, \gamma \in [0, 1]$ with $\alpha + \beta + \gamma = 1$

**Computational Requirements:**
- Hardware: Single-node NVIDIA A100 GPU (40GB VRAM) or equivalent
- Training time: ~48 hours per module (parallelizable across modules)
- Inference: <1 second per protocol on CPU (enabling deployment without GPU infrastructure)

### 3.4 Experimental Design for Validation

#### 3.4.1 Multi-Site Pilot Study

**Study Design**: Quasi-experimental pre-post intervention with matched controls and randomized feature configurations.

**Participant Recruitment**:
- **Sampling frame**: 200 academic medical centers in US conducting ≥10 trials/year (identified via ClinicalTrials.gov sponsor analysis)
- **Stratification**: Match institutions by annual research budget quartile, clinical trial volume, and therapeutic area focus
- **Allocation**: 
  - 50 institutions invited to pilot program (intervention group)
  - 50 institutions matched controls (no intervention)
  - 100 institutions reserve pool

**Randomized Feature Configurations** (within pilot group):
To test causal mechanisms, pilot institutions receive randomized configurations:

| Configuration | Modularity | GUI | Source Code Access | n |
|---------------|------------|-----|-------------------|---|
| Full (F) | 4 modules | Web GUI | Full GitHub access | 15 |
| Modular-CLI (MC) | 4 modules | CLI only | Full GitHub access | 10 |
| Monolithic (M) | Single integrated | Web GUI | Binary distribution | 10 |
| Minimal (Min) | 1 module only | Web GUI | Full GitHub access | 15 |

This $2 \times 2 \times 2$ factorial design enables testing:
- **H2a**: Modularity effect (F+MC vs. M+Min)
- **H2b**: GUI effect (F+M vs. MC+Min)
- **H2c**: Transparency effect (F+MC+Min vs. M)

**Timeline**:
- **Month 0**: Baseline survey (current trial optimization practices, pain points, budget allocation)
- **Month 1**: Framework release and deployment support
- **Months 3, 6, 9, 12**: Follow-up surveys and usage analytics
- **Month 18**: Final evaluation (publications, sustained usage, consortium participation)

#### 3.4.2 Primary Outcome Measures

**Outcome 1: Institutional Adoption Rate**

*Definition*: Binary indicator of successful deployment (institution completes installation, conducts ≥1 trial analysis, and reports results to research team).

*Measurement*:
- Deployment confirmation via institutional IT department
- Usage logs showing ≥1 protocol analysis per month for ≥3 consecutive months
- Institutional announcement (email, website, or internal newsletter)

*Success Criterion*: ≥10 pilot institutions (20% of pilot cohort) achieve deployment within 12 months.

*Statistical Test*:
$$H_0: p_{\text{pilot}} \leq p_{\text{control}}$$
$$H_1: p_{\text{pilot}} > p_{\text{control}}$$

Chi-square test comparing deployment rates between pilot and control groups ($\alpha = 0.05$).

**Power Analysis**:
With $n=50$ pilot institutions, study has 80% power to detect deployment rate difference of 15% (20% pilot vs. 5% control) assuming effect size $w = 0.30$.

**Outcome 2: Research Productivity**

*Definition*: Count of peer-reviewed publications citing or utilizing OpenTrialAI framework.

*Measurement*:
- Monthly PubMed and Semantic Scholar searches for framework citations
- Author surveys to identify unpublished manuscripts in preparation
- GitHub repository "Used By" tracking

*Success Criterion*: ≥5 publications within 18 months.

*Statistical Test*:
Poisson regression modeling publication rate over time:
$$\log(\lambda_t) = \beta_0 + \beta_1 \cdot t + \beta_2 \cdot \text{deployments}_t$$

where $\lambda_t$ is expected publication count at month $t$.

**Outcome 3: System Usability**

*Definition*: Mean System Usability Scale (SUS) score from clinical trial coordinators.

*Measurement*:
- Standardized 10-item SUS questionnaire administered after ≥1 month of use
- Sample: ≥30 users per deployment site (minimum 5 sites = 150 total users)
- Likert scale responses (1-5) converted to SUS score (0-100)

*Success Criterion*: Mean SUS ≥70 (Good usability threshold).

*Statistical Test*:
One-sample t-test against null hypothesis $\mu_{\text{SUS}} = 70$:
$$t = \frac{\bar{x}_{\text{SUS}} - 70}{s / \sqrt{n}}$$

With $n=150$ users, study has 80% power to detect SUS difference of 5 points (SD=12.5, $\alpha=0.05$).

**Outcome 4: Consortium Sustainability**

*Definition*: Number of code contributions (pull requests merged) from consortium members.

*Measurement*:
- GitHub repository analytics tracking contributor affiliations
- Classification: Bug fixes, feature additions, module extensions, documentation
- Temporal analysis: Contribution rate over 18-month period

*Success Criterion*: ≥12 contributions from ≥3 different institutions within 18 months.

*Statistical Test*:
Negative binomial regression modeling contribution count:
$$\log(\mu_i) = \beta_0 + \beta_1 \cdot \text{institution\_size}_i + \beta_2 \cdot \text{deployment\_duration}_i$$

#### 3.4.3 Secondary Analyses

**Mediation Analysis** (Testing Causal Mechanism):

To test whether cost reduction → deployment → research output, employ structural equation modeling:

```
Cost Savings → Deployment Success → Publication Count
     ↓                                      ↑
     └──────────────────────────────────────┘
              (Direct Effect)
```

Estimate indirect effect using bootstrap confidence intervals (5000 iterations).

**Subgroup Analyses**:
- **By institution size**: Large (>$500M research budget) vs. small (<$500M)
- **By therapeutic focus**: Oncology vs. other areas
- **By prior AI experience**: Institutions with existing ML infrastructure vs. none

**Sensitivity Analyses**:
- **Missing data**: Multiple imputation for incomplete survey responses
- **Attrition**: Inverse probability weighting for institutions dropping out
- **Contamination**: Intention-to-treat analysis (institutions randomized to pilot but not deploying still counted)

### 3.5 Regulatory Pathway

#### 3.5.1 FDA 510(k) Submission Strategy

**Device Classification**: Class II Medical Device (Clinical Decision Support Software)

**Predicate Devices**:
- AI-ECG clinical decision support (Lopez-Jimenez et al., 2025)
- Medication-related clinical decision support software (Nanji et al., 2022)

**Submission Components**:

1. **Device Description**: Detailed technical documentation of all four modules, including algorithms, training data sources, and performance characteristics

2. **Intended Use Statement**: 
   > "OpenTrialAI is intended to provide clinical trial coordinators and principal investigators with decision support recommendations for protocol design, patient recruitment strategies, outcome risk assessment, and safety monitoring. The device provides recommendations to inform human decision-making and does not autonomously modify trial protocols or make patient care decisions."

3. **Performance Testing**:
   - **Analytical validation**: Algorithm performance on held-out test set (n=65,000 trials)
     - Recruitment Engine: AUC ≥0.75 for feasibility prediction
     - Protocol Optimizer: Mean absolute error ≤20% for timeline prediction
     - Outcome Predictor: Brier score ≤0.20 for success probability
     - Safety Monitor: Sensitivity ≥0.80 for known adverse events
   
   - **Clinical validation**: Prospective evaluation at 5 pilot sites
     - Agreement with expert clinician judgment: Cohen's κ ≥0.60
     - User acceptance: SUS ≥70
     - Error rate: <5% critical errors (recommendations contradicting established guidelines)

4. **Software Documentation**:
   - Software Development Lifecycle (SDLC) following IEC 62304
   - Version control and change management procedures
   - Cybersecurity risk assessment (NIST framework)
   - Audit trail specifications (21 CFR Part 11 compliance)

5. **Labeling**:
   - User manual with clinical use instructions
   - Warnings and limitations (e.g., "Not for use in autonomous protocol modification")
   - Training materials for clinical trial coordinators

**Timeline**:
- Month 12: Pre-submission meeting with FDA
- Month 18: Submit 510(k) application
- Month 21-24: FDA review and response to questions
- Month 24: Target clearance date

#### 3.5.2 Open-Source Compliance Strategy

**Transparency Documentation**:
- Public GitHub repository with complete source code
- Data provenance documentation (all training data from public registries)
- Model cards (Mitchell et al., 2019) for each module describing intended use, performance characteristics, and limitations

**Quality Management System**:
- Automated testing (unit tests, integration tests, regression tests)
- Continuous integration/continuous deployment (CI/CD) pipeline
- Issue tracking and bug reporting procedures
- Security vulnerability disclosure policy

**Regulatory Precedent**:
Following clinDataReview (Cougnaud et al., 2024), demonstrate that open-source tools CAN achieve regulatory acceptance through:
- Comprehensive validation documentation
- Audit trail implementation
- Version control and release management
- User training and support infrastructure

### 3.6 Evaluation Metrics Summary

| Metric Category | Specific Metric | Target | Measurement Method |
|-----------------|-----------------|--------|-------------------|
| **Adoption** | Institutional deployments | ≥10 (20%) | Deployment logs + surveys |
| **Research** | Publications | ≥5 papers | PubMed/Scholar search |
| **Usability** | SUS score | ≥70 | Standardized questionnaire |
| **Sustainability** | Code contributions | ≥12 PRs | GitHub analytics |
| **Performance** | Recruitment AUC | ≥0.75 | Test set evaluation |
| **Performance** | Protocol MAE | ≤20% | Test set evaluation |
| **Performance** | Outcome Brier score | ≤0.20 | Test set evaluation |
| **Performance** | Safety sensitivity | ≥0.80 | Known AE detection |
| **Clinical** | Expert agreement | κ ≥0.60 | Clinician ratings |
| **Regulatory** | FDA clearance | ≤24 months | Submission timeline |

## 4. Expected Outcomes & Impact

### 4.1 Expected Technical Outcomes

**Framework Deliverables**:
1. **Production-ready software**: Fully documented, tested, and deployable framework with Docker containers, Kubernetes configurations, and institutional IT integration guides
2. **Trained models**: Four independently deployable modules with pre-trained weights achieving target performance metrics (AUC ≥0.75, MAE ≤20%, Brier ≤0.20, Sensitivity ≥0.80)
3. **Web interface**: Clinical user interface achieving SUS ≥70 with wizard-style workflows, interactive visualizations, and PDF report generation
4. **API specifications**: RESTful APIs with OpenAPI documentation, FHIR compatibility, and authentication/authorization infrastructure

**Performance Expectations**:
OpenTrialAI is expected to achieve 50-60% of commercial platform performance (30-40% absolute improvement in enrollment/timeline metrics versus 65% commercial baseline). This performance gap reflects the fundamental trade-off between proprietary patient-level EHR data (commercial platforms) and public trial-level registry data (OpenTrialAI). However, this level of performance is sufficient for decision support use cases where recommendations augment rather than replace human judgment.

**Validation Results**:
- **Analytical validation**: Test set performance meeting FDA Class II thresholds across all four modules
- **Clinical validation**: Prospective evaluation at 5 pilot sites demonstrating substantial agreement (κ ≥0.60) with expert clinician judgment
- **Usability validation**: Mean SUS score ≥70 from ≥150 clinical trial coordinators across diverse institutional settings

### 4.2 Expected Adoption Outcomes

**Institutional Deployment**:
Based on the multi-site pilot study design, we expect:
- **12-month adoption**: 10-15 institutions (20-30% of pilot cohort) complete deployment
- **18-month sustained use**: 8-12 institutions (16-24%) maintain active usage (≥1 analysis/month)
- **Geographic distribution**: Deployments across ≥3 US regions and ≥1 international site
- **Therapeutic diversity**: Adoptions spanning oncology, cardiology, neurology, and rare diseases

**Adoption Barriers Identified**:
The pilot study will systematically identify barriers through:
- Exit interviews with non-adopting institutions
- Usage analytics revealing feature utilization patterns
- IT department surveys on deployment challenges

Expected barriers include:
- Institutional IT security policies restricting cloud-based tools
- Lack of GPU infrastructure for local deployment
- Insufficient clinical trial coordinator training time
- Competing priorities during deployment period

**Mitigation Strategies**:
- Provide multiple deployment options (cloud, on-premise, hybrid)
- Optimize inference for CPU-only environments
- Develop asynchronous training modules (video tutorials, documentation)
- Offer flexible deployment timelines with dedicated support

### 4.3 Expected Research Impact

**Publication Outcomes**:
We anticipate ≥5 peer-reviewed publications within 18 months across three categories:

1. **Framework Description** (1-2 papers):
   - Primary publication in *Nature Digital Medicine* or *JAMIA* describing OpenTrialAI architecture, training procedures, and validation results
   - Methods paper in *Journal of Clinical and Translational Science* detailing deployment best practices

2. **Methodological Innovations** (2-3 papers):
   - Novel algorithms for protocol optimization using counterfactual reasoning
   - Transfer learning approaches for low-resource therapeutic areas
   - Fairness analysis of recruitment recommendations across demographic groups

3. **Application Studies** (1-2 papers):
   - Retrospective analysis of historical trial failures using OpenTrialAI predictions
   - Prospective case studies from pilot institutions demonstrating real-world impact

**Research Enablement**:
Beyond direct publications, OpenTrialAI enables academic researchers to:
- **Benchmark new algorithms**: Standardized evaluation framework for comparing trial optimization methods
- **Investigate research questions**: Transparent codebase allows hypothesis testing about trial design principles
- **Develop domain-specific extensions**: Modular architecture facilitates contributions (e.g., pediatric trial module, adaptive design optimizer)

**Comparison to Commercial Platforms**:
Unlike proprietary platforms that prevent algorithmic research (black-box systems, no publication rights for methods), OpenTrialAI's open-source nature explicitly enables research contributions. This shifts clinical trial AI from a commercial product to a research infrastructure, analogous to how arXiv transformed preprint sharing or GitHub transformed code collaboration.

### 4.4 Expected Regulatory Impact

**FDA Clearance**:
We expect FDA 510(k) clearance within 24 months based on:
- **Precedent devices**: Successful clearances for AI-based clinical decision support (AI-ECG, medication decision support)
- **Regulatory positioning**: Class II decision support (moderate risk) rather than Class III autonomous systems (high risk)
- **Validation rigor**: Comprehensive analytical and clinical validation exceeding typical software device submissions

**Regulatory Precedent Establishment**:
OpenTrialAI's clearance would establish critical precedents:
1. **Open-source acceptability**: Demonstrates that FDA accepts open-source medical AI with proper documentation and quality management
2. **Public data sufficiency**: Validates that public trial registries provide adequate data for regulatory-grade decision support
3. **Transparency benefits**: Shows that algorithmic transparency can enhance rather than hinder regulatory review

**Post-Market Surveillance**:
Following clearance, we will implement:
- Adverse event reporting system for recommendation errors
- Quarterly performance monitoring reports
- User feedback collection and analysis
- Software updates following FDA guidance on modifications requiring new submissions

### 4.5 Expected Ecosystem Impact

**Consortium Sustainability**:
We expect a self-sustaining consortium model with:
- **Founding members**: 5-10 academic medical centers committing to governance participation
- **Contribution patterns**: ≥12 code contributions within 18 months from ≥3 institutions
- **Governance structure**: Steering committee with rotating leadership, technical working groups for each module, and annual community meetings

**Community Growth**:
Beyond founding consortium, we anticipate:
- **GitHub engagement**: 500+ stars, 50+ forks, 20+ external contributors within 24 months
- **User community**: Online forum with 200+ registered users, monthly office hours, and annual user conference
- **Educational adoption**: Integration into 5+ graduate-level courses on clinical trial design or medical AI

**Ecosystem Comparison**:
Target ecosystem metrics comparable to successful open-source medical AI projects:
- **MONAI** (medical imaging): 774 citations, global adoption, consortium-led
- **Chemprop** (molecular property prediction): 2,200+ GitHub stars, industry-standard tool
- **DiffSBDD** (structure-based drug design): 343 citations, 446 GitHub stars, active research community

### 4.6 Broader Impact on Drug Development

**Cost Savings**:
Academic institutions deploying OpenTrialAI save $100K-500K annually in commercial platform licensing fees. With 10 initial deployments, this represents $1-5M in aggregate annual savings, enabling budget reallocation to:
- Additional trial sites or patient recruitment efforts
- Biostatistician or data manager salaries
- Investigator-initiated trial funding

**Timeline Acceleration**:
Even achieving 30-40% improvement (versus 65% commercial baseline) translates to meaningful clinical impact:
- Average Phase II trial duration: 24 months → 14-17 months with OpenTrialAI
- Average Phase III trial duration: 36 months → 22-25 months with OpenTrialAI
- Cumulative time savings: 12-20 months per drug development program

**Equity and Access**:
Democratization particularly benefits:
- **Academic medical centers**: Enable participation in trial optimization AI previously restricted to industry-sponsored trials
- **Rare disease research**: Low-volume trials cannot justify commercial platform costs; OpenTrialAI provides accessible alternative
- **Low- and middle-income countries**: International academic institutions gain access to decision support tools without prohibitive licensing fees
- **Early-career researchers**: Junior investigators can leverage AI tools without requiring institutional enterprise licenses

**Methodological Transparency**:
Open-source nature enables:
- **Reproducible research**: Other researchers can verify and build upon published methods
- **Bias detection**: Community can audit algorithms for fairness issues (e.g., demographic disparities in recruitment recommendations)
- **Regulatory trust**: Transparent algorithms facilitate regulatory review and public confidence in AI-driven trial design

### 4.7 Limitations and Future Directions

**Known Limitations**:
1. **Performance ceiling**: Public registry data lacks patient-level granularity available to commercial platforms, limiting prediction accuracy for tasks requiring EHR integration
2. **Infrastructure dependency**: Requires institutional IT support for deployment, excluding small independent research groups
3. **Regulatory scope**: Limited to decision support; cannot provide autonomous protocol optimization or direct patient care decisions
4. **Language barrier**: Initial version supports English-language protocols only
5. **Data recency**: Public registry data has 6-12 month publication lag, limiting real-time monitoring capabilities

**Future Research Directions**:
1. **Federated learning**: Enable institutions to collaboratively train models on local patient data without sharing sensitive information
2. **Adaptive trial design**: Extend framework to support Bayesian adaptive designs and platform trials
3. **Multilingual support**: Develop models for non-English trial protocols (Chinese, Spanish, French)
4. **Real-time monitoring**: Integrate with institutional EHR systems (with appropriate data use agreements) for live trial monitoring
5. **Causal inference**: Incorporate causal discovery methods to identify protocol features causally linked to trial success

**Scalability Path**:
- **Year 1-2**: Establish framework and achieve initial adoption (10 institutions)
- **Year 3-4**: Expand consortium to 20-30 institutions, pursue international deployments
- **Year 5+**: Transition to foundation model (e.g., OpenTrialAI Foundation) with sustainable funding from institutional memberships, grants, and philanthropic support

### 4.8 Success Criteria Summary

The research will be considered successful if it achieves:

**Primary Success Criteria** (all must be met):
1. ✓ **Adoption**: ≥10 institutional deployments within 12 months
2. ✓ **Research**: ≥5 peer-reviewed publications within 18 months
3. ✓ **Usability**: Mean SUS ≥70 from clinical users
4. ✓ **Regulatory**: FDA 510(k) clearance within 24 months

**Secondary Success Criteria** (≥3 of 5 must be met):
1. ✓ **Sustainability**: ≥12 code contributions from ≥3 institutions within 18 months
2. ✓ **Performance**: Test set metrics meeting targets (AUC ≥0.75, MAE ≤20%, Brier ≤0.20, Sensitivity ≥0.80)
3. ✓ **Clinical validation**: Expert agreement κ ≥0.60
4. ✓ **Community**: GitHub repository achieves 500+ stars within 24 months
5. ✓ **Cost impact**: Documented cost savings ≥$1M aggregate across adopting institutions

**Transformative Impact Indicators** (aspirational):
- OpenTrialAI becomes cited as standard tool in clinical trial design courses
- FDA references framework in guidance documents on AI-based trial optimization
- Pharmaceutical companies adopt OpenTrialAI for investigator-initiated trial support
- International regulatory agencies (EMA, PMDA) accept framework for trial submissions

This research has the potential to fundamentally transform clinical trial AI from a proprietary enterprise tool to public research infrastructure, democratizing access for academic researchers and accelerating the development of life-saving therapies through transparent, community-driven innovation.